ArticleCancer medicine2026
Years of Life Lost of Patients With Early Adenocarcinoma of the Esophagogastric Junction Compared to Esophageal or Gastric Adenocarcinoma. A Registry-Based Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis registry-based study investigates patients with resected esophageal (EAC), cardiac (CAC), and gastric (GAC) pT1 adenocarcinoma (AC) concerning epidemiological, tumor-related, and prognostic factors, analyzing especially the impact on survival and years of life lost (YLL).
backgroundAs CAC is classified as esophageal cancer in the 7th and more specified in the 8th edition of the UICC-TNM classification, it remains unclear if significant differences exist for pT1 CAC in comparison to EAC and GAC.
methodsWe used the ICD-O-3 code comparing tumors in the esophagus (C15.0-C15.9), cardia (C16.0), and stomach (C16.1-C16.9). A total of 246,653 patients with these tumors were documented between 2010-2020 in the German Cancer Registry. Only ACs with histologically confirmed tumor infiltration into mucosa or submucosa (pT1) were included. YLL were calculated using life expectancy data from Germany.
resultsThe study population consists of 9.442 patients with resected pT1 AC. Age and sex differed significantly between CAC (n = 1.870) and EAC (n = 2.018) as well as between CAC and GAC (n = 5.554). Tumor-related factors were significantly different between the three locations. Multivariate analysis showed significantly worse prognosis for CAC compared to the other locations. The median of YLL was 10.7 years for EAC, 8.5 years for CAC and 6.8 years for GAC (p < 0.0001).
conclusionPatients with pT1 AC of the cardia differ from patients with EAC or GAC in terms of demographic, tumor-related factors, prognosis, and YLL. Therefore, separate classification of tumors originating in the cardia is useful. Future studies should investigate the influence of therapy on prognosis and YLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.